Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan - interim analysis in post-marketing surveillance

Amyloid. 2019;26(sup1):45-46. doi: 10.1080/13506129.2019.1582508.

Authors

Tomonori Ishii¹, Yoshiki Sekijima², Yukio Ando³

Affiliations

¹ a Pfizer Japan Inc. , Tokyo , Japan.
² b School of Medicine, Shinshu University School of Medicine , Matsumoto , Japan.
³ c Department of Neurology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto , Japan.

PMID: 31343289
DOI: 10.1080/13506129.2019.1582508

No abstract available

MeSH terms

Age of Onset
Aged
Amyloid Neuropathies, Familial / drug therapy*
Amyloid Neuropathies, Familial / genetics
Amyloid Neuropathies, Familial / pathology
Benzoxazoles / administration & dosage*
Female
Humans
Japan
Male
Middle Aged
Mutation
Prealbumin / genetics*
Product Surveillance, Postmarketing

Substances

Benzoxazoles
Prealbumin
tafamidis

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related